Sana Biotechnology Statistics
Total Valuation
SANA has a market cap or net worth of $1.06 billion. The enterprise value is $983.18 million.
| Market Cap | 1.06B |
| Enterprise Value | 983.18M |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SANA has 299.36 million shares outstanding. The number of shares has increased by 17.07% in one year.
| Current Share Class | 299.36M |
| Shares Outstanding | 299.36M |
| Shares Change (YoY) | +17.07% |
| Shares Change (QoQ) | +6.79% |
| Owned by Insiders (%) | 6.27% |
| Owned by Institutions (%) | 47.39% |
| Float | 190.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.87 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.38 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -152.87% and return on invested capital (ROIC) is -52.15%.
| Return on Equity (ROE) | -152.87% |
| Return on Assets (ROA) | -29.16% |
| Return on Invested Capital (ROIC) | -52.15% |
| Return on Capital Employed (ROCE) | -60.13% |
| Weighted Average Cost of Capital (WACC) | 14.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.49M |
| Employee Count | 142 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.61% in the last 52 weeks. The beta is 2.10, so SANA's price volatility has been higher than the market average.
| Beta (5Y) | 2.10 |
| 52-Week Price Change | +6.61% |
| 50-Day Moving Average | 3.34 |
| 200-Day Moving Average | 3.74 |
| Relative Strength Index (RSI) | 53.90 |
| Average Volume (20 Days) | 2,437,864 |
Short Selling Information
The latest short interest is 42.15 million, so 14.08% of the outstanding shares have been sold short.
| Short Interest | 42.15M |
| Short Previous Month | 39.74M |
| Short % of Shares Out | 14.08% |
| Short % of Float | 22.07% |
| Short Ratio (days to cover) | 15.13 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -185.06M |
| Pretax Income | -211.82M |
| Net Income | -211.82M |
| EBITDA | -174.19M |
| EBIT | -185.06M |
| Earnings Per Share (EPS) | -$0.76 |
Balance Sheet
The company has $160.49 million in cash and $80.94 million in debt, with a net cash position of $79.55 million or $0.27 per share.
| Cash & Cash Equivalents | 160.49M |
| Total Debt | 80.94M |
| Net Cash | 79.55M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 154.57M |
| Book Value Per Share | 0.52 |
| Working Capital | 46.88M |
Cash Flow
In the last 12 months, operating cash flow was -$132.24 million and capital expenditures -$2.82 million, giving a free cash flow of -$135.06 million.
| Operating Cash Flow | -132.24M |
| Capital Expenditures | -2.82M |
| Depreciation & Amortization | 10.87M |
| Net Borrowing | -360,000 |
| Free Cash Flow | -135.06M |
| FCF Per Share | -$0.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SANA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.07% |
| Shareholder Yield | -17.07% |
| Earnings Yield | -19.93% |
| FCF Yield | -12.71% |
Analyst Forecast
The average price target for SANA is $8.43, which is 137.47% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.43 |
| Price Target Difference | 137.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |